

Mission Bio, Abiosciences to co-develop bioinformatics for clinical research applications in China

30 December 2022 | News

The companies will begin with a collaboration to improve single-cell analytics for haematologic cancers



US-based Mission Bio and Abiosciences have announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in haematological cancers. The goal is to combine Mission Bio's industry-leading single-cell DNA and multi-omics capabilities with Abiosciences' cutting-edge artificial intelligence (AI) expertise, to uncover new disease signatures and address therapeutic resistance. These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.

Mission Bio's Tapestri Platform is a powerful tool that has been adopted increasingly for translational research and clinical trials, both at biopharma companies and in academia.

Abiosciences will leverage its AI platform and bioinformatics expertise to create a unique and advanced bioinformatic analytical algorithm, in order to gain deeper and more comprehensive insights into disease progression, development of resistance, and single-cell multi-omics analysis for researchers in China. Mission Bio will support Abiosciences with its unique Tapestri single-cell multi-omics platform, custom panels, subject matter experts, and R&D expertise.

"Through the numerous algorithms and AI platforms exclusively developed by the company, we can more flexibly and effectively process the huge amount of data generated by single cell sequencing, find more valuable clinical therapeutic biomarkers, and help the translate the technology for clinical use," said Tao Hong, Co-Founder & Chief Operating Officer at Abiosciences.